BRAF and colorectal carcinoma: Indeed, in the largest series published by the Mayo Clinic of 21 patients who underwent resection of liver metastases from BRAF-mutated CRC, the mean progression free survival (mPFS) and mOS were longer than in the non-metastasectomy cohort (13.6 and 29.1 months vs. 6.2 and 22.7, respectively), with one patient who remained relapse-free for more than two years.